CGI Pharmaceuticals is dedicated to novel drug discovery and development by applying its proprietary ASKA™ technology to solve many of the issues in identifying and validating targets and drugs to the key enzyme class of kinases. In addition to collaborations with Eli Lilly, Serono, Affymetrix, and Pfizer, CGI is in late preclinical studies for three internal drug discovery programs. Flagship General Partner Doug Cole is a board member.

www.cgipharma.com